Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

Klaus Podar, MD, PhD, Melissa Simoncini, BS, Yu-Tzu Tai, PhD, Martin Sattler, PhD, Kenji Ishitsuka, MD, PhD, Steven Le Gouill, MD, Makoto Hamasaki, MD, PhD, Renate Burger, PhD, Noopur Raje, MD, Teru C. Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Kenneth Anderson, MD

Blood (2004) 104 (11): 3352.

https://doi.org/10.1182/blood.V104.11.3352.3352

Published: 2004

Journal Articles

Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma.

Steven Le Gouill, MD, Klaus Podar, MD PhD, Teru Hideshima, MD, Emmanuel Zorn, PhD, Melissa Simoncini, BS, Jean-Luc Harousseau, MD, Kenneth C. Anderson, MD.

Blood (2004) 104 (11): 2445.

https://doi.org/10.1182/blood.V104.11.2445.2445

Published: 2004

Journal Articles

Effects of the Indazolylpyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.

Klaus Podar, MD, PhD, Melissa Simoncini, BS, Steven Le Gouill, MD, Yu-Tzu Tai, PhD, Shaji Kumar, MD, Pierfrancesco Tassone, MD, Laurence P. Catley, MD, Lini N. Pandite, MD, Rakesh Kumar, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2452.

https://doi.org/10.1182/blood.V104.11.2452.2452

Published: 2004

Journal Articles

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

Klaus Podar, MD, PhD, Reshma Shringarpure, PhD, Yu-Tzu Tai, PhD, Melissa Simoncini, BS, Martin Sattler, PhD, Kenji Ishitsuka, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Anderson C. Kenneth, MD

Blood (2004) 104 (11): 2453.

https://doi.org/10.1182/blood.V104.11.2453.2453

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma.

Effects of the Indazolylpyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

Email alerts

ASH Publications

American Society of Hematology

Update search

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma.

Effects of the Indazolylpyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only